Nonalcoholic Steatohepatitis Therapeutics Market, By Drug Type (Obeticholic, Aramchol, Saroglitazar &Elafibranor)
The NASH market is segmented based on drug type which includes potential phase III candidates such as Obeticholic acid (OCA), Aramchol, Saroglitazar and Elafibranor. Moreover, the report enlists the candidates in Phase I and Phase II clinical trials. Based on the drug type, Elafibranor is expected to account for a major share of this market and the market for Elafibranor is expected to grow at the highest CAGR. This growth in revenue is majorly due to Elafibranor which is considered to be the most advanced drug in this category.
The Nonalcoholic Steatohepatitis Therapeutics market has been segmented as follows:
Global Nonalcoholic Steatohepatitis (NASH) Therapeutics Market, By Drug Type
- Potential Drug Candidates in Phase III
- Obeticholic Acid (OCA)
- Aramchol (arachidyl amido cholanoic acid)
Nonalcoholic fatty liver disease (NAFLD) is a disorder categorized by excess fat in the liver of people who drink little to no alcohol. No direct cause has yet been identified, however obesity and insulin resistance are believed to have major roles. Most often, NAFLD goes relatively undetected, as a liver can remain fatty without obstructing its function. Though, NAFLD can progress into a far more severe condition known as nonalcoholic steatohepatitis (NASH), a disease characterized by inflammation and irreversible cell death. NASH is a disease that advances over time. Over a period of ten years up to 20% of patients with NASH develop cirrhosis of the liver, and 10% die from the disease. At present, NASH is one of the leading causes of liver transplants in the U.S., with a considerable proportion of the general population currently suffering from the disease. NAFLD and NASH are both closely related to diabetes and obesity, and together are now considered as the leading cause of liver disease in Western countries. Thus, there is an urgent need for effective treatment options for these diseases. The need for treatment is expected to propel the growth of NASH therapeutics in coming years.
Browse the full Nonalcoholic Steatohepatitis Therapeutics Market (Obeticholic Acid, Aramchol, Saroglitazar, and Elafibranor) – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 – 2025 report at http://www.transparencymarketresearch.com/nonalcoholic-steatohepatitis-market.html
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Each TMR syndicated research report covers a different sector – such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
USA – Canada Toll Free: 866-552-3453